Stock Purchase Warrant Sample Contracts

Sito Mobile, Ltd. – SITO Mobile, Ltd. Stock Purchase Warrant (July 5th, 2019)

This Warrant is issued pursuant to, and is subject to the terms and conditions of, that certain Secured Subordinated Convertible Note and Warrant Purchase Agreement (the “Agreement”) dated June 28, 2019.

Castle Biosciences Inc – STOCK PURCHASE WARRANT To Purchase Shares of Series E‑1 Preferred Stock of CASTLE BIOSCIENCES, INC. (June 26th, 2019)

THIS CERTIFIES that, for value received, [__________] (the “Investor”), is entitled, upon the terms and subject to the conditions hereinafter set forth, at any time on or after the date set forth in Section 2 below and on or prior to the close of business on the date ten (10) years after the date hereof; but not thereafter, to subscribe for and purchase, from CASTLE BIOSCIENCES, INC., a Delaware corporation (the “Company”), [_______] shares of Series E‑1 Preferred Stock of the Company at a purchase price of $[____] per share. The purchase price and the number of shares for which the Warrant is exercisable shall be subject to adjustment as provided herein. This Warrant is one of the Warrants issued pursuant to that Amendment No. 1 to Convertible Subordinated Promissory Notes of even date herewith by and among the Company and the Note Holders (as defined therein) (the “Notes Amendment”).

Findex Com Inc – Stock Purchase Warrant (June 12th, 2019)

This Warrant is issued in connection with that certain Securities Exchange Agreement dated as of June __, 2019, by and between the Company and the Registered Holder.

Findex Com Inc – Stock Purchase Warrant (June 12th, 2019)

This Warrant is issued in connection with that certain Securities Exchange Agreement dated as of June __, 2019, by and between the Company and the Registered Holder.

Castle Biosciences Inc – STOCK PURCHASE WARRANT To Purchase Shares of Series E‑1 Preferred Stock of CASTLE BIOSCIENCES, INC. (May 14th, 2019)

THIS CERTIFIES that, for value received, [__________] (the “Investor”), is entitled, upon the terms and subject to the conditions hereinafter set forth, at any time on or after the date set forth in Section 2 below and on or prior to the close of business on the date ten (10) years after the date hereof; but not thereafter, to subscribe for and purchase, from CASTLE BIOSCIENCES, INC., a Delaware corporation (the “Company”), [_______] shares of Series E‑1 Preferred Stock of the Company at a purchase price of $[____] per share. The purchase price and the number of shares for which the Warrant is exercisable shall be subject to adjustment as provided herein. This Warrant is one of the Warrants issued pursuant to that Amendment No. 1 to Convertible Subordinated Promissory Notes of even date herewith by and among the Company and the Note Holders (as defined therein) (the “Notes Amendment”).

Innovation Pharmaceuticals Inc. – FORM OF SERIES 4 PREFERRED STOCK PURCHASE WARRANT INNOVATION PHARMACEUTICALS INC. (May 10th, 2019)

THIS SERIES 4 PREFERRED STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 6:00 p.m. (New York City time) on ______, 20201 (provided that, if such date is not a Trading Day, then such date shall be the immediately following Trading Day) (the “Termination Date”) but not thereafter, to subscribe for and purchase from Innovation Pharmaceuticals Inc., a Nevada corporation (the “Company”), up to _____ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Series B 5% Convertible Preferred Stock of the Company (the “Preferred Stock”); provided, however, that, in the event of an Authorized Share Failure (as defined in the Purchase Agreement) or a Registration Statement Availability Failure, for each day of an Authorized Share Failure and for each

Helios & Matheson Analytics Inc. – PLACEMENT AGENT PREFERRED STOCK PURCHASE WARRANT Helios and Matheson Analytics Inc. (March 26th, 2019)

THIS PLACEMENT AGENT PREFERRED STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that Shareholder Approval is obtained and deemed effective (the “Initial Exercise Date”), and on or prior to 5:00 p.m. (New York City time) on the five year anniversary of the Initial Exercise Date (the “Termination Date”), but not thereafter, to subscribe for and purchase from Helios and Matheson Analytics Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Series B Preferred Stock, par value $0.01 per share (the “Preferred Stock”). The purchase price of one share of Preferred Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that

Helios & Matheson Analytics Inc. – SERIES F-[1][2] PREFERRED STOCK PURCHASE WARRANT Helios and Matheson Analytics Inc. (March 26th, 2019)

THIS SERIES F-[1][2] PREFERRED STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [March 25, 2019]1 [the date that Shareholder Approval is obtained and deemed effective]2 (the “Initial Exercise Date”), and on or prior to 5:00 p.m. (New York City time) on the five-year anniversary of the Initial Exercise Date (the “Termination Date”), but not thereafter, to subscribe for and purchase from Helios and Matheson Analytics Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Series B Preferred Stock, par value $0.01 per share (the “Preferred Stock”). The purchase price of one share of Preferred Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Kraig Biocraft Laboratories, Inc – STOCK PURCHASE WARRANT To Purchase [ ]1 Shares of Class A Common Stock of Kraig Biocraft Laboratories, Inc. (March 11th, 2019)

This Warrant is issued to ________________ (“Holder”) by Kraig Biocraft Laboratories, Inc., a Wyoming corporation (the “Company”), in connection with a certain Securities Purchase Agreement dated [ ], 2019 by and between the Company and Holder (the “Purchase Agreement”).

MAGELLAN GOLD Corp – STOCK PURCHASE WARRANT To Purchase _______________ Shares of Common Stock of MAGELLAN GOLD CORPORATION (December 20th, 2018)

THIS CERTIFIES that, for value received, _________________________________, or assigns (the "Holder"), is entitled, upon the terms and subject to the conditions hereinafter set forth, at any time on or after the date of issuance of this Warrant (the "Initial Exercise Date") and on or prior to the close of business on a date that is three (3) months following the effective date of a Registration Statement on Form S-1 registering for resale the Warrant Shares (defined below) under the Securities Act of 1933, as amended (the "Termination Date") unless sooner terminated in accordance with the Agreement as hereinbelow defined but not thereafter, to subscribe for and purchase from Magellan Gold Corporation, a Nevada corporation (the "Company"), up to ______________________________ (_______________) shares (the "Warrant Shares") of Common Stock, $0.001 par value per share of the Company (the "Common Stock"). The purchase price of one share of Common Stock (the "Exercise Price") under this War

MAGELLAN GOLD Corp – STOCK PURCHASE WARRANT To Purchase _______________ Shares of Common Stock of MAGELLAN GOLD CORPORATION (December 20th, 2018)

THIS CERTIFIES that, for value received, _________________________________, or assigns (the "Holder"), is entitled, upon the terms and subject to the conditions hereinafter set forth, at any time on or after the date of issuance of this Warrant (the "Initial Exercise Date") and on or prior to the close of business on a date that is six (6) months following the effective date of a Registration Statement on Form S-1 registering for resale the Warrant Shares (defined below) under the Securities Act of 1933, as amended (the "Termination Date") unless sooner terminated in accordance with the Agreement as hereinbelow defined but not thereafter, to subscribe for and purchase from Magellan Gold Corporation, a Nevada corporation (the "Company"), up to ______________________________ (_______________) shares (the "Warrant Shares") of Common Stock, $0.001 par value per share of the Company (the "Common Stock"). The purchase price of one share of Common Stock (the "Exercise Price") under this Warra

Onconova Therapeutics, Inc. – ONCONOVA THERAPEUTICS, INC. FIRST AMENDMENT TO UNDERWRITER SERIES A CONVERTIBLE PREFERRED STOCK PURCHASE WARRANT (November 14th, 2018)

Reference is made to that certain Underwriter Series A Convertible Preferred Stock Purchase Warrant (the “Warrant”) issued by Onconova Therapeutics, Inc. (the “Company”) on February 12, 2018 to H.C. Wainwright & Co., LLC (“HCW”) as the underwriter for the Company’s February 2018 public offering of securities (with respect to 49,737.5 Series A Preferred Stock).  All capitalized terms used and not otherwise defined herein have the respective meanings given to them in the Warrant.

Adial Pharmaceuticals, Inc. – FORM OF STOCK PURCHASE WARRANT (November 14th, 2018)

THIS CERTIFIES THAT, for value received, [        ] (“Holder”) or its assigns, is entitled to purchase from Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), at any time or from time to time during the period specified in Paragraph 2 hereof and subject to adjustment as provided herein, [        ] fully paid and nonassessable shares of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”), at an exercise price per share equal to $5.00 per share of Common Stock (the “Exercise Price”). The term “Warrant Shares,” as used herein, refers to the shares of Common Stock purchasable hereunder. The Warrant Shares and the Exercise Price are subject to adjustment as provided in Paragraph 4 hereof. The term “Warrant” means this Stock Purchase Warrant issued pursuant to that certain Exchange Agreement, dated November 12, 2018, by and among the Company and Holder.

Adial Pharmaceuticals, Inc. – FORM OF STOCK PURCHASE WARRANT (November 14th, 2018)

THIS CERTIFIES THAT, for value received, [            ] (“Holder”) or its assigns, is entitled to purchase from Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), at any time or from time to time during the period specified in Paragraph 2 hereof and subject to adjustment as provided herein, [                      ] fully paid and nonassessable shares of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”), at an exercise price per share equal to $6.25 per share of Common Stock (the “Exercise Price”). The term “Warrant Shares,” as used herein, refers to the shares of Common Stock purchasable hereunder. The Warrant Shares and the Exercise Price are subject to adjustment as provided in Paragraph 4 hereof. The term “Warrant” means this Stock Purchase Warrant issued pursuant to that certain Exchange Agreement, dated November 12, 2018, by and among the Company and Holder.

Innovation Pharmaceuticals Inc. – SERIES [1/2/3] PREFERRED STOCK PURCHASE WARRANT INNOVATION PHARMACEUTICALS INC. (October 9th, 2018)

THIS SERIES [1/2/3] PREFERRED STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 6:00 p.m. (New York City time) on _______1 (provided that, if such date is not a Trading Day, then such date shall be the immediately following Trading Day) (the “Termination Date”) but not thereafter, to subscribe for and purchase from Innovation Pharmaceuticals Inc., a Nevada corporation (the “Company”), up to ______2 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Series B 5% Convertible Preferred Stock of the Company (the “Preferred Stock”); provided, however, that, in the event of an Authorized Share Failure (as defined in the Purchase Agreement) or a Registration Statement Availability Failure, for each day of an Authorized Share Failure and for

Adial Pharmaceuticals, Inc. – STOCK PURCHASE WARRANT (June 11th, 2018)

THIS CERTIFIES THAT, for value received, David S Nagelberg 2003 Revocable Trust Dtd 7/2/03 (“Holder”) or its assigns, is entitled to purchase from Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), at any time or from time to time during the period specified in Paragraph 2 hereof and subject to adjustment as provided herein, 300,000 fully paid and nonassessable shares of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”), at an exercise price per share equal to $3.75 per share of Common Stock (the “Exercise Price”). The term “Warrant Shares,” as used herein, refers to the shares of Common Stock purchasable hereunder. The Warrant Shares and the Exercise Price are subject to adjustment as provided in Paragraph 3and Paragraph 5 hereof. The term “Warrant” means this Stock Purchase Warrant issued pursuant to that certain Securities Purchase Agreement, dated June 3, 2018, by and among the Company and the Investor listed on the execution page thereof

Greenway Technologies Inc – Greenway Technologies, Inc. Stock Purchase Warrant Expiring: January 8, 2021. (May 21st, 2018)

THIS IS TO CERTIFY that, for value received, Kent Harer (the "Holder") is entitled at any time from the date hereof, but prior to 5:00 pm, Fort Worth, Texas time on January 8, 2021, subject to and upon the terms and conditions herein, to purchase up to 4,000,000 fully paid and non-assessable shares of the common stock, par value $0.0001 per share (the "Common Stock") of GREENWAY TECHNOLOGIES, INC. (formerly known as UMED Holdings, Inc.), a Texas corporation (the "Company") at a purchase price of $.15 (fifteen cents) per share (the "Exercise Price") of the Common Stock, after taking into account the restrictive nature of the shares of the Common Stock as described below (such number of shares of the Common Stock and the purchase price being subject to adjustment as provided herein). This Warrant shall be void and of no effect and all rights hereunder shall cease at 5:00 pm, Fort Worth, Texas time on January 8, 2021, except to the extent therefore exercised, provided that in the case of

Onconova Therapeutics, Inc. – SERIES B CONVERTIBLE PREFERRED STOCK PURCHASE WARRANT ONCONOVA THERAPEUTICS, INC. (April 30th, 2018)

THIS PREFERRED STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the 18-month anniversary of the date (the “Charter Amendment Date”) on which the Company (as defined below) publicly announces through the filing of a Current Report on Form 8-K that the amendment to the Company’s certificate of incorporation to sufficiently increase the Company’s authorized shares of Common Stock to cover the conversion of all then-outstanding shares of Preferred Stock into Common Stock has been filed with the Secretary of State of the State of Delaware (the “Termination Date”), provided that, if such date is not a Trading Day, the Termination Date should be the immediately following Trading Day but not thereafter, to

Onconova Therapeutics, Inc. – SERIES B CONVERTIBLE PREFERRED STOCK PURCHASE WARRANT ONCONOVA THERAPEUTICS, INC. (April 25th, 2018)

THIS PREFERRED STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the 18-month anniversary of the date (the “Charter Amendment Date”) on which the Company (as defined below) publicly announces through the filing of a Current Report on Form 8-K that the amendment to the Company’s certificate of incorporation to sufficiently increase the Company’s authorized shares of Common Stock to cover the conversion of all then-outstanding shares of Preferred Stock into Common Stock has been filed with the Secretary of State of the State of Delaware (the “Termination Date”), provided that, if such date is not a Trading Day, the Termination Date should be the immediately following Trading Day but not thereafter, to

Arista Financial Corp. – STOCK PURCHASE WARRANT To Subscribe for and Purchase Common Stock of ARISTA FINANCIAL CORP. VOID AFTER _________ (April 17th, 2018)

THIS CERTIFIES that, for value received, [HOLDER], or registered assigns, (the “Holder”) is entitled to subscribe for and purchase from ARISTA FINANCIAL CORP., a Nevada corporation with an address of 51 JFK Parkway; First Floor West; Short Hills, New Jersey 07078, (the “Company”), at an exercise price of _______ Dollars ($____) per share (the “Warrant Price”), at any time prior to 5:00 p.m., EST, on ___________, up to _____________ (________) shares of fully paid, nonassessable shares of the Company’s Common Stock, subject, however, to the provisions and upon the terms and conditions hereinafter set forth. As used herein the term “Common Stock” shall mean shares of common stock of the Company, $0.001 par value, authorized by the Company’s Articles of Incorporation.

Greenway Technologies Inc – Greenway Technologies, Inc. Stock Purchase Warrant Expiring: November 30, 2020. (April 16th, 2018)

THIS IS TO CERTIFY for value received, MTG Holdings LTD (the "Holder") is entitled at any time from the date hereof, but prior to 5:00pm, Fort Worth, Texas time on November 30, 2020, subject to and upon the terms and conditions herein, to purchase up to 1,000,000 (one million) fully paid and nonassessable shares of the common stock, par value $0.0001 per share (the "Common Stock") of GREENWAY TECHNOLOGIES, INC., a Texas corporation (the "Company") at a purchase price of $0.30 (thirty cents) per share (the "Exercise Price") of the Common Stock, after taking into account the restrictive nature of the shares of the Common Stock as described below (such number of shares of the Common Stock and the purchase price being subject to adjustment as provided herein). This Warrant shall be void and of no effect and all rights hereunder shall cease at 5:00pm, Fort Worth, Texas time on November 30, 2020, except to the extent therefore exercised, provided that in the case of the earlier dissolution

Adial Pharmaceuticals, Inc. – STOCK PURCHASE WARRANT (April 16th, 2018)

THIS CERTIFIES THAT, for value received, ___________________ (“Holder”) or its assigns, is entitled to purchase from Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), at any time or from time to time during the period specified in Paragraph 2 hereof and subject to adjustment as provided herein, _________ fully paid and nonassessable shares of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”), at an exercise price per share equal to $________ per share of Common Stock (the “Exercise Price”). The term “Warrant Shares,” as used herein, refers to the shares of Common Stock purchasable hereunder. The Warrant Shares and the Exercise Price are subject to adjustment as provided in Paragraph 4 hereof. The term “Warrant” means this Stock Purchase Warrant issued pursuant to that certain Securities Purchase Agreement, dated ___________ __, 2018, by and among the Company and the Investor listed on the execution page thereof (the “Securities Purchase Agre

Adial Pharmaceuticals, Inc. – STOCK PURCHASE WARRANT (April 16th, 2018)

THIS CERTIFIES THAT, for value received, ___________________ (“Holder”) or its assigns, is entitled to purchase from Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), at any time or from time to time during the period specified in Paragraph 2 hereof and subject to adjustment as provided herein, _________ fully paid and nonassessable shares of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”), at an exercise price per share equal to $________ per share of Common Stock (the “Exercise Price”). The term “Warrant Shares,” as used herein, refers to the shares of Common Stock purchasable hereunder. The Warrant Shares and the Exercise Price are subject to adjustment as provided in Paragraph 4 hereof. The term “Warrant” means this Stock Purchase Warrant issued pursuant to that certain Securities Purchase Agreement, dated ___________ __, 2018, by and among the Company and the Investor listed on the execution page thereof (the “Securities Purchase Agre

NEUROONE MEDICAL TECHNOLOGIES Corp – NEUROONE MEDICAL TECHNOLOGIES CORPORATION CAPITAL STOCK PURCHASE WARRANT (March 16th, 2018)

This Certified That, for value received, [NAME OF HOLDER] (the “Holder”) is entitled to subscribe for and purchase from NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), at any time commencing on the Conversion Date and expiring on November 21, 2021 (the “Warrant Exercise Term”), the Shares at the Exercise Price (each as defined in Section 1 below).

NEUROONE MEDICAL TECHNOLOGIES Corp – NEUROONE MEDICAL TECHNOLOGIES CORPORATION CAPITAL STOCK PURCHASE WARRANT (March 16th, 2018)

This Certified That, for value received, [NAME OF HOLDER] (the “Holder”) is entitled to subscribe for and purchase from NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), at any time commencing on the Conversion Date and expiring on November 21, 2021 (the “Warrant Exercise Term”), the Shares at the Exercise Price (each as defined in Section 1 below).

Onconova Therapeutics, Inc. – SERIES A CONVERTIBLE PREFERRED STOCK PURCHASE WARRANT ONCONOVA THERAPEUTICS, INC. (February 8th, 2018)

THIS PREFERRED STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received,               or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the later of  (i) the one-year anniversary of the date on which we publicly announce through the filing of a Current Report on Form 8-K that the amendment to our certificate of incorporation to sufficiently increase our authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock has been filed with the Secretary of State of the State of Delaware (the “Charter Amendment Date”) and (ii) the earlier of (A) the one-month anniversary of the date on which the Company (as defined below) publicly releases its top-line results of the INSPIRE Pivotal phase 3 that compare

Onconova Therapeutics, Inc. – UNDERWRITER SERIES A CONVERTIBLE PREFERRED STOCK PURCHASE WARRANT ONCONOVA THERAPEUTICS, INC. (February 8th, 2018)

THIS UNDERWRITER PREFERRED STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received,               or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the later of  (i) the one-year anniversary of the date on which we publicly announce through the filing of a Current Report on Form 8-K that the amendment to our certificate of incorporation to sufficiently increase our authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock has been filed with the Secretary of State of the State of Delaware (the “Charter Amendment Date”) and (ii) the earlier of (A) the one-month anniversary of the date on which the Company (as defined below) publicly releases its top-line results of the INSPIRE Pivotal phase 3 t

Onconova Therapeutics, Inc. – UNDERWRITER SERIES A CONVERTIBLE PREFERRED STOCK PURCHASE WARRANT ONCONOVA THERAPEUTICS, INC. (February 7th, 2018)

THIS UNDERWRITER PREFERRED STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received,               or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the later of  (i) the one-year anniversary of the date on which we publicly announce through the filing of a Current Report on Form 8-K that the amendment to our certificate of incorporation to sufficiently increase our authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock has been filed with the Secretary of State of the State of Delaware (the “Charter Amendment Date”) and (ii) the earlier of (A) the one-month anniversary of the earlier of the date on which the Company (as defined below) publicly release top-line data analysis results for our

Onconova Therapeutics, Inc. – SERIES A CONVERTIBLE PREFERRED STOCK PURCHASE WARRANT ONCONOVA THERAPEUTICS, INC. (February 7th, 2018)

THIS PREFERRED STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received,               or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the later of  (i) the one-year anniversary of the date on which we publicly announce through the filing of a Current Report on Form 8-K that the amendment to our certificate of incorporation to sufficiently increase our authorized shares of Common Stock to cover the conversion of all outstanding shares of Preferred Stock into Common Stock has been filed with the Secretary of State of the State of Delaware (the “Charter Amendment Date”) and (ii) the earlier of (A) the one-month anniversary of the earlier of the date on which the Company (as defined below) publicly release top-line data analysis results for our Phase 3 INSP

NEUROONE MEDICAL TECHNOLOGIES Corp – NEUROONE MEDICAL TECHNOLOGIES CORPORATION CAPITAL STOCK PURCHASE WARRANT (December 20th, 2017)

This Capital Stock Purchase Warrant (this “Warrant”) is issued in connection with the Company’s private offering solely to accredited investors of up to $1,500,000 (or such higher amount as the Company’s Board of Directors shall determine) aggregate principal amount of Convertible Promissory Notes (the “Notes”) and related Warrants in accordance with, and subject to, the terms and conditions described in the Amended and Restated Subscription Agreement, dated as of [ ] (the “Subscription Agreement”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to those terms in the Notes or the Subscription Agreement, as the case may be.

NEUROONE MEDICAL TECHNOLOGIES Corp – SECOND AMENDMENT TO CAPITAL STOCK PURCHASE WARRANTS (November 27th, 2017)

This Second Amendment to Capital Stock Purchase Warrants (this “Amendment”) is made effective as of this [    ]th day of November, 2017, by and between NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), and each of those persons and entities, severally and not jointly, who are holders of the Company’s Capital Stock Purchase Warrants (each, a “Holder” and collectively, the “Holders”).

Weed, Inc. – STOCK PURCHASE WARRANT (November 16th, 2017)

THIS IS TO CERTIFY that, for value received, XXXXXX., a Arizona corporation and/or assigns (the “Holder”) is entitled, subject to the terms and conditions set forth herein, to purchase from WEED Inc., a Nevada corporation (the “Company”) up to XXXXXXXXXXXXXXXX (XXX,XXX) fully paid and nonassessable shares of common stock of the Company (the “Warrant Securities”) at the initial price of $3.00 (Three Dollars) per share but subject to adjustment as provided in Section 3 below, (the “Exercise Price”), upon payment by cashier’s check or wire transfer of the Exercise Price for such shares of the Common Stock to the Company at the Company’s offices.

Arqule Inc – SERIES A PREFERRED STOCK PURCHASE WARRANT ARQULE, INC. (November 8th, 2017)

THIS SERIES A PREFERRED STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after November 7, 2017 (the “Initial Exercise Date”) and on or prior to the close of business on the fourth-year anniversary of the date of the Stockholder Filing (as defined in the Purchase Agreement) (such 4th anniversary, the “Termination Date”) but not thereafter, to subscribe for and purchase from ArQule, Inc., a Delaware corporation (the “Company”), (i) prior to the Stockholder Filing, up to ______ shares of Series A Preferred Stock or (ii) after the Stockholder Filing, up to ___ shares of Common Stock (together with the Series A Preferred Stock and as subject to adjustment hereunder, the “Warrant Shares”). The purchase price for each Warrant Share shall be equal to the Exercise Price as defined in Section 2(d)

RenovaCare, Inc. – RENOVACARE, INC. SERIES __ STOCK PURCHASE WARRANT (October 18th, 2017)

Renovacare, Inc., a Nevada corporation (the “Company”), hereby certifies that [●], its permissible transferees, designees, successors and assigns (collectively, the “Holder”), for value received, is entitled to purchase from the Company at any time and from time to time commencing on the date first appearing above (the “Issuance Date”), up to and through 12:01a.m. (EST) on the date five (5) years from the Issuance Date (the “Termination Date”) up to [●] shares (each, a “Share" and collectively the “Shares”) of the Company's common stock, par value $0.00001 (the “Common Stock”), at an exercise price per Share of $_____ (the “Exercise Price”). The number of Shares purchasable hereunder and the Exercise Price are subject to adjustment as provided in Section 4 hereof.

PwrCor, Inc. – FORM OF CLASS A COMMON STOCK PURCHASE WARRANT (October 18th, 2017)

THIS CLASS A COMMON STOCK PURCHASE WARRANT (this “Warrant”) CERTIFIES that, for value received, [___________]. (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date of issuance of this Warrant (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York time) on the second anniversary of the issuance of this Warrant (the “Termination Date”) but not thereafter, to subscribe for and purchase from PwrCor, Inc. a Delaware corporation (the “Company”), up to ____________________ (_____) shares (the “Warrant Shares”) of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”).  The purchase price per share of Common Stock (the “Exercise Price”) under this Warrant shall be $0.30 subject to adjustment hereunder.